Rockwell Medical Inc. (RMTI)
1.17
-0.02 (-1.68%)
At close: Apr 25, 2025, 3:59 PM
1.14
-2.56%
After-hours: Apr 25, 2025, 04:09 PM EDT
Rockwell Medical Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Dec 31, 2018 |
|---|---|---|---|---|---|
| Concentrate Products Revenue | 28.3M | 22.66M | 59.7M | 21.57M | 16.79M |
| Concentrate Products Revenue Growth | +24.88% | -62.04% | +176.72% | +28.52% | n/a |
| Drug Revenue Revenue | 11K | 11K | 141K | 2.2M | 68K |
| Drug Revenue Revenue Growth | 0.00% | -92.20% | -93.58% | +3130.88% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|
| Non-Us Revenue | 9.27M | 598K | 241K | 226K | 273K |
| Non-Us Revenue Growth | +1450.00% | +148.13% | +6.64% | -17.22% | n/a |
| United States Revenue | 74.34M | 561K | 835K | 910K | 272K |
| United States Revenue Growth | +13151.87% | -32.81% | -8.24% | +234.56% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.3M | 4.04M | 4.37M | 3.25M | 3.44M | 3.83M | 3.75M | 4.15M | 4.02M | 5.3M | 4.27M | 4.74M | 5.42M | 5.14M | 5.77M | 6.55M | 5.29M | 4.87M | 7.35M | 6.56M | 6.45M | 7.72M | 9.32M | 7.9M | 6.16M | 5.69M | 5.06M | 5.87M | 4.79M | 6.54M | 6.1M | 6.05M | 5.07M | 5.01M | 4.99M | 6.09M | 3.83M | 3.84M | 5.33M |
| Selling, General, and Administrative Revenue Growth | +6.64% | -7.67% | +34.50% | -5.69% | -9.93% | +2.05% | -9.69% | +3.34% | -24.24% | +24.06% | -9.81% | -12.62% | +5.38% | -10.89% | -11.82% | +23.76% | +8.70% | -33.74% | +12.01% | +1.67% | -16.39% | -17.24% | +18.01% | +28.27% | +8.23% | +12.43% | -13.76% | +22.50% | -26.75% | +7.22% | +0.84% | +19.32% | +1.11% | +0.55% | -18.11% | +59.08% | -0.20% | -27.98% | n/a |
| Research and Development Revenue | n/a | n/a | 18K | 168K | 494K | 167K | 278K | 156K | 469K | 926K | 1.57M | 1.39M | 1.22M | 2.42M | 1.81M | 1.91M | 1.75M | 1.62M | 1.82M | 1.96M | 1.47M | 2.96M | 497.28K | 2.71M | 808.19K | 1.56M | 1.67M | 2.13M | 1.3M | 1.68M | 1.21M | 1.2M | 1.26M | 2.06M | 1.31M | 2.03M | 1.25M | 885.26K | 799.59K |
| Research and Development Revenue Growth | n/a | -100.00% | -89.29% | -65.99% | +195.81% | -39.93% | +78.21% | -66.74% | -49.35% | -40.91% | +12.73% | +13.84% | -49.46% | +33.55% | -5.24% | +9.40% | +7.96% | -11.26% | -6.88% | +32.63% | -50.15% | +494.90% | -81.64% | +235.17% | -48.16% | -6.45% | -21.63% | +62.99% | -22.13% | +37.92% | +1.18% | -4.84% | -38.84% | +56.97% | -35.24% | +62.81% | +40.83% | +10.71% | n/a |
| Sales and Marketing Revenue | 726K | 586K | 594K | 541K | 556K | 530K | 498K | 352K | 762K | 526K | 455K | 873K | 1.54M | 1.47M | 1.85M | 2.13M | 1.67M | 2M | 2.07M | 1.9M | 1.83M | 2.22M | 3.1M | 288.17K | 121.87K | 164.37K | 215.08K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +23.89% | -1.35% | +9.80% | -2.70% | +4.91% | +6.43% | +41.48% | -53.81% | +44.87% | +15.60% | -47.88% | -43.35% | +4.97% | -20.69% | -13.22% | +27.80% | -16.41% | -3.68% | +9.03% | +4.03% | -17.64% | -28.47% | +976.58% | +136.45% | -25.86% | -23.58% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |